Sun Pharma’s subsidiary will invest Rs 3,000 crore in a new manufacturing facility in Madhya Pradesh. The company also launched its innovative drug Ilumya® in India. Despite a premium valuation, technical indicators suggest a generally bullish trend for the stock.